Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient

Pharmacotherapy

Volumn 20, Issue 3, 2000, Pages 292-307

  Wazny, Lori D ^b   Ariano, Robert E ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ALCOHOL; ALLOPURINOL; AMIODARONE; AMPHOTERICIN B; AMPICILLIN; AMRINONE; ANTINEOPLASTIC AGENT; CAPTOPRIL; CARBAMAZEPINE; CEFOTETAN; CEFTAZIDIME; CORTICOSTEROID; COTRIMOXAZOLE; CYANOCOBALAMIN; DANAPAROID; FOLIC ACID; HEPARIN; INTERLEUKIN 11; LEPIRUDIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; QUINIDINE; QUININE; RECOMBINANT INTERLEUKIN 11; RIFAMPICIN; THROMBOCYTE ANTIBODY; THROMBOPOIETIN; UNINDEXED DRUG;

ACUTE DISEASE; ALGORITHM; BONE MARROW SUPPRESSION; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; IMMUNE MEDIATED INJURY; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0034007257     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.4.292.34883     Document Type: Review

References (99)

1. Bonfiglio MF, Traeger SM, Kier KL, et al. Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients. Ann Pharmacother 1995;29:835-42.
2. George JN, Raskob GE, Rizvi Shah S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129:886-90.
3. Burnakis GB. Inaccurate assessment of drug-induced thrombocytopenia: reason for concern. Ann Pharmacother 1994;28:726-9.
4. Van der Weerdt CM. Thrombocytopenia due to quinidine or quinine: report on a series of 28 patients. Vox Sang 1967;12:265-72.
5. Jacobson ES. Fatal immune thrombocytopenia induced by ethchlorvynol. Ann Intern Med 1972;77:73-6.
6. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
7. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
8. Levine SP. Thrombocytopenia caused by immunologic platelet destruction. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's clinical hematology, 10th ed. Baltimore: Williams & Wilkins, 1999:1583-1611.
9. Arrowsmith ER, Greer JP, Macon WR. Complications of hematopoietic neoplasms. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's clinical hematology, 10th ed. Baltimore: Williams & Wilkins, 1999:2033-75.
10. Glatt AE, Anand A. Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Clin Infect Dis 1995;21:415-23.
11. Bithell TC. Thrombocytopenia caused by immunologic platelet destruction: idiopathic thrombocytopenic purpura (ITP), drug-induced thrombocytopenia, and miscellaneous forms. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's clinical hematology, 9th ed. Philadelphia: Lea & Febiger, 1993:1329-55.
12. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: diagnosis, natural history, and treatment options. Postgrad Med 1998;103(2):169-78.
13. Sanofi Winthrop. Product monograph, Primator (milrinone), New York, NY; 1996
14. Ansell JE, Price JM, Shah S, et al. Heparin-induced thrombocytopenia: what is its real frequency? Chest 1985;88:878-82.
15. Cawley MJ, Wittbrodt ET, Boyce EG, Skaar DJ. Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy 1999;19:108-13.
16. Shalansky SJ, Verma AK, Levine M. Factors to consider before discontinuing heparin in patients who develop thrombocytopenia. Pharmacotherapy 1999;19:1011-12.
17. Huffman LM. Sodium valproate and thromhocytopenia. Can Med Assoc J 1982;126:358-9.
18. Winfield DA, Benton P, Espir MLE, et al. Sodium valproate and thrombocytopenia. Br Med J 1976;2:981.
19. Brichard B, Vermylen C, Scheiff JM, et al. Haematological disturbances during long-term valproate therapy. Eur J Pediatr 1994;153:378-80.
20. Carney R, Nasreddine W, Drury I, et al. Relation between thrombocytopenia and valproate dose [abstr]. Epilepsia 1997;38(suppl8):102.
21. Laster JL, Cikrit D, Walker N, et al. The heparin-induced thrombocytopenia syndrome: an update. Surgery 1987;102(4):763-70.
22. Stead RB, Schafer AI, Rosenberg RD, et al. Heterogeneity of heparin lots associated with thrombocytopenia and thromboembolism. Am J Med 1984;77:185-8.
23. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984;100:535-40.
24. Rutherford CJ, Frenkel EP. Thrombocytopenia: issues in diagnosis and therapy. Med Clin North Am 1994;78(3):555-75.
25. Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984;59:123-5.
26. Vukelja SJ, Krishnan J, Diehl LF. Mean platelet volume improves upon the megathrombocyte index but cannot replace the blood film examination in the evaluation of thrombocytopenia. Am J Hematol 1993;44:89-94.
27. Paulus JM, Aster RH. Clinical evaluation of thrombokinetics. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. Hematology, 3rd ed. New York: McGraw-Hill, 1983:1196-1201.
28. Stenberg PL, Hill RJ. Platelets and megakaryocytes. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's clinical hematology, 10th ed. Baltimore: Williams & Wilkins, 1999:615-60.
29. Heilmann E, Friese P, Anderson S, et al. Biotinylated platelets: a new approach to the measurement of platelet life span. Br J Haematol 1993;85:729-35.
30. Pulkrabek SM. Platelet antibodies. Clin Lab Med 1996; 16(4):817-35.
31. Gupta AK, Kovacs MJ, Sauder DN. Heparin-induced thrombocytopenia. Ann Pharmacother 1998;32:55-9.
32. Brieger DB, Mak KH, Kottke-Marchant K, et al. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31: 1449-59.
33. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998;79:1-7.
34. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
35. 14C serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995;104:648-54.
36. Leach MF, Cooper LK, AuBuchon JP. Detection of drug-dependent, platelet-reactive antibodies by solid-phase red cell adherence assays. Br J Haematol 1997;97:755-61.
37. Eisner EV, Crowell EB. Hydrochlorothiazide dependent thrombocytopenia due to IgM antibody. JAMA 1971;215:480-2.
38. Blajchman J, Lowry RC, Pettit JE, et al. Rifampicin-induced immune thrombocytopenia. Br Med J 1970;3(713):24-6.
39. Sandler RM. IgM platelet autoantibody due to sodium valproate. Br Med J 1958;2:1502-10.
40. Eisner EV, Shahidi NT. Immune thrombocytopenia due to a drug metabolite. N Engl J Med 1972;287:376-81.
41. Giffiths E, Dzik WH. Assays for heparin-induced thrombocytopenia. Transfus Med 1997;7:1-11.
42. Lee DH, Warkentin TE, Denomme GA, et al. A diagnostic test for heparin-induced thrombocytopenia; detection of platelet microparticles using flow cytometry. Br J Haematol 1996;95:724-31.
43. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost 1992;68:95-6.
44. Kiefel V, Santoso S, Schmidt S, et al. Metabolite-specific (IgG) and drug-specific antibodies IgG, IgM in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia. Transfusion 1987;27:262-5.
45. Hackett T, Kelton JG, Powers P. Drug-induced platelet destruction. Semin Thromb Hemost 1982;8(2):116-37.
46. Kutti J, Weinfeld A. The frequency of thrombocytopenia in patients with heart disease treated with oral diuretics. Acta Med Scand 1968;183:245-50.
47. Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;36:2-6.
48. Okafor KC, Griffin C, Ngole PM. Hydrochlorothiazide-induced thrombocytopenic purpura. Drug Intell Clin Pharm 1986; 20:60-1.
49. Ball P. Thrombocytopenia and purpura in patients receiving chlorothiazide and hydrochlorothiazide. JAMA 1960;173(6):663-5.
50. Duncan A, Moore SB, Barker P. Thrombocytopenia caused by frusemide-induced platelet antibody. Lancet 1981;1(8231): 1210.
51. Kean WF, Dwosh IL, Anastassiades TP, Ford PM, Kelly HG. The toxicity pattern of d-penicillamine therapy. Arthritis Rheum 1980;23(2):158-64.
52. Brichard B, Vermylen C, Scheiff JM, Ninane J, Cornu G. Haematological disturbances during long-term valproate therapy. Eur J Pediatr 1994;153:378-80.
53. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after abciximab therapy. Circulation 1997;95(4):809-13.
54. Ferrari E, Thiry M, Touati C, Gibelin P, Baudouy M. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;96(10):3809-10.
55. Garratty G. Immune cytopenia associated with antibiotics. Trans Med Rev 1993;7:255-67.
56. Meisner DJ, Carlson RJ, Gottlieb AJ. Thrombocytopenia following sustained release procainamide. Arch Intern Med 1985;145:700-2.
57. Chong BH, Berndt MC, Koutts J, et al. Quinidine-induced thrombocytopenia and leukopenia: demonstration and characterization of distinct antiplatelet and antileukocyte antibodies. Blood 1983;62:1218-23.
58. Castro O. Quinidine leukopenia and thrombocytopenia with drug-dependent leukoagglutination [letter]. N Engl J Med 1977;296:572.
59. Zeigler Z, Shadduck RK, Winkelstein A, et al. Immune hemolytic anemia and thrombocytopenia secondary to quinidine: in vitro studies of the quinidine-dependent red cell and platelet antibodies. Blood 1979;77:306-10.
60. Stroncek DF, Vercellotti GM, Hammerschmidt DE, Christie DJ, Shankar RA, Jacob HS. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood 1992;80:241-8.
61. Gottschall JL, Nearhing B, McFarland JG, et al. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol 1994;47:283-9.
62. Weinberger I, Rotenberg Z, Fuchs J, et al. Amiodarone-induced thrombocytopenia. Arch Intern Med 1987;147:735-6.
63. Saphir JR, Ney RG. Delayed thrombocytopenic purpura after diminutive gold therapy JAMA 1966;195:782-4.
64. Stafford BT, Crosby WH. Late onset of gold-induced thrombocytopenia, with a practical note on the injections of dimercaprol. JAMA 1978;239:50-1.
65. England JM, Smith DS. Gold-induced thrombocytopenia and response to dimercaprol. Br Med J 1972;2:748-9.
66. Korbitz BC, Eisner E. Cocktail purpura - quinine-dependent thrombocytopenia. Rocky Mt Med J 1973;70(10):38-41.
67. Belkin GA. Cocktail purpura - an unusual case of quinine sensitivity. Ann Intern Med 1967;66(3):583-6.
68. Murray JA, Abbott I, Anderson DA, Morgan AD. Bitter lemon purpura. Br Med J 1979;2(6204):1551-2.
69. Bolton FG, Dameshek W. Thrombocytopenic purpura due to quinidine. Clinical studies. Blood 1956;11:527-46.
70. Gesnik MH, Bradford HA. Thromhocytopenic purpura associated with hydrochlorothiazide therapy. JAMA 1960;172:556-9.
71. Magnusson B, Rodjer S. Alprenolol-induced thrombocytopenia. Acta Med Scand 1980;207:231-3.
72. Young RC, Nachman RL, Horowitz HI. Thrombocytopenia due to digitoxin. Demonstration of antibody and mechanisms of action. Am J Med 1966;41:605-14.
73. Moss RA. Drug-induced immune thrombocytopenia. Am J Hematol 1980;9:439-46.
74. Guay DRP, Richard A. Heparin-induced thrombocytopenia - association with a platelet aggregating factor and cross-sensitivity to bovine and porcine heparin. Drug Intell Clin Pharm 1984;18:398-401.
75. Kinney EL, Ballard JO, Carlin B, et al. Amrinone-mediated thrombocytopenia. Scand J Haematol 1983;31:376-80.
76. Mattingly PM, Burnette PK, Weston MW, et al. Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone. Ann Pharmacother 1990;24:1172-4.
77. Ross MP, Allen-Webb EM, Pappas JB, et al. Amrinone-associated thrombocytopenia: pharmacokinetic analysis. Clin Pharmacol Ther 1993;53(6):661-7.
78. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. N Engl J Med 1986;314:349-58.
79. Baker JF, Edelson J. Metabolism and pharmacokinetics of milrinone in laboratory animals. In: Braunwald E, Sonnenblick EH, Chakrin LW, Schwarz RP, eds. Milrinone: investigation of new inotropic therapy for congestive heart failure. New York: Raven Press, 1984:49-53.
80. Gafter U, Zevin D, Komlos L, et al. Thrombocytopenia associated with hypersensitivity to ranitidine: possible cross-reactivity with cimetidine. Am J Gastroenterol 1989;84(5): 560-2.
81. Shalev O, Seror D. Cimetidine and ranitidine may not cross-react to cause thrombocytopenia. J Intern Med 1991;230:87-8.
82. Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 1997;52:183-9.
83. Newland AC. The problem of thrombocytopenia and its management. Anticancer Drugs 1995;6(suppl 5):65-73.
84. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1992;35:802-12.
85. Genetics Institute, Inc. Neumega (oprelvekin) package insert. Cambridge, MA;1997.
86. Tepler I, Laurence E, Smith JW, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87(9):3607-14.
87. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997;15(11):3368-77.
88. Kaviani MD, Mason LE, Bree AG, et al. Effects of recombinant human interleukin-11 on the activation and morphology of peripheral blood platelets and megakaryocytes in nonhuman primates [abstr]. Blood 1996;88(suppl 1):26a.
89. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase 1 trial of recombinant human interleukin-11 in women with breast cancer receiving chemotherapy. Blood 1996;87(9): 3615-24.
90. Kaushansky K. Thrombopoietin. N Engl J Med 1998;339(11): 746-54.
91. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336:404-9.
92. Baser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase 1 trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997;89:3118-28.
93. Vadhan-Raj S, Verschraegen C, McGarry L, et al. Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin C-induced thrombocytopenia in patients with gynecologic malignancy [abstr]. Blood 1997;90(suppl 1):580a.
94. Vadhan-Raj S. Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol 1998; 35(3):261-8.
95. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996;88:511-21.
96. Hoechst Marion Roussel. Refludan (lepirudin) package insert. Kansas City, MO;1998.
97. Greinacher A, Volpel H, Potzsch B. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT) [abstr]. Blood 1996;88(suppl 1):281a.
98. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:4895-510.
99. Organen Inc. Orgaran (danaparoid sodium) product information. West Orange, NJ; 1996.